InsidersTradesSigma
Total declarations
Company
▲ Purchases (29 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by Aquilo Capital Management, LLC. Officer active across 1 companies, notably Spero Therapeutics, Inc.. In total, 29 filings have been recorded. Total volume traded: €25.4m. The latest transaction was filed on 26 April 2022 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations29 total
€195,39539,727 shares@ €4.91840.15% mcap0.8% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000015:0·
Ideal exit: 21 Jan 2023 (T+270)
€260,73533,115 shares@ €7.87360.20% mcap1.0% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000014:0·
Ideal exit: 25 Dec 2022 (T+270)
€109,53415,702 shares@ €6.97580.083% mcap0.4% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000013:0·
Ideal exit: 9 Dec 2022 (T+270)
€253,37229,729 shares@ €8.52270.19% mcap1.0% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000011:0·
Ideal exit: 25 Nov 2022 (T+270)
€120,56414,828 shares@ €8.13080.092% mcap0.5% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000010:0·
Ideal exit: 15 Nov 2022 (T+270)
€1m125,000 shares@ €10.38890.99% mcap10.6% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000004·
Ideal exit: 28 Oct 2022 (T+270)
€1m125,000 shares@ €10.38890.99% mcap5.1% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000004:0·
Ideal exit: 28 Oct 2022 (T+270)
€15,3581,599 shares@ €9.60470.012% mcap0.1% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000003·
Ideal exit: 21 Oct 2022 (T+270)
€15,3581,599 shares@ €9.60470.012% mcap0.1% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000003:0·
Ideal exit: 21 Oct 2022 (T+270)
€527,54948,488 shares@ €10.880.40% mcap4.3% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000002·
Ideal exit: 15 Oct 2022 (T+270)
€527,54948,488 shares@ €10.880.40% mcap2.1% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000002:0·
Ideal exit: 15 Oct 2022 (T+270)
€100,9428,867 shares@ €11.3840.077% mcap0.8% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000001·
Ideal exit: 7 Oct 2022 (T+270)
€100,9428,867 shares@ €11.3840.077% mcap0.4% of flow
Common Stock, $0.001 par value
SEC:0001591986-22-000001:0·
Ideal exit: 7 Oct 2022 (T+270)
€976,83175,493 shares@ €12.93940.74% mcap8.0% of flow
Common Stock, $0.001 par value
SEC:0001691902-22-000001·
Ideal exit: 25 Sept 2022 (T+270)
€976,83175,493 shares@ €12.93940.74% mcap3.8% of flow
Common Stock, $0.001 par value
SEC:0001691902-22-000001:0·
Ideal exit: 25 Sept 2022 (T+270)
€2m150,000 shares@ €15.00781.71% mcap18.4% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000016·
Ideal exit: 26 Jul 2022 (T+270)
€2m150,000 shares@ €15.00781.71% mcap8.9% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000016:0·
Ideal exit: 26 Jul 2022 (T+270)
€2m134,543 shares@ €16.11271.65% mcap17.7% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000015·
Ideal exit: 27 Jun 2022 (T+270)
€2m134,543 shares@ €16.11271.65% mcap8.5% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000015:0·
Ideal exit: 27 Jun 2022 (T+270)
€694,78344,210 shares@ €15.71550.53% mcap5.7% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000014·
Ideal exit: 10 Jun 2022 (T+270)
€694,78344,210 shares@ €15.71550.53% mcap2.7% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000014:0·
Ideal exit: 10 Jun 2022 (T+270)
€387,10924,749 shares@ €15.64140.29% mcap3.2% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000013·
Ideal exit: 6 Jun 2022 (T+270)
€387,10924,749 shares@ €15.64140.29% mcap1.5% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000013:0·
Ideal exit: 6 Jun 2022 (T+270)
€667,00444,042 shares@ €15.14470.51% mcap5.5% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000012·
Ideal exit: 27 May 2022 (T+270)
€667,00444,042 shares@ €15.14470.51% mcap2.6% of flow
Common Stock, $0.001 par value
SEC:0001591986-21-000012:0·
Ideal exit: 27 May 2022 (T+270)
25 of 29 declarations
About Aquilo Capital Management, LLC
Aquilo Capital Management, LLC is a significant shareholder of Spero Therapeutics, Inc.
